Metsera Announces Positive Phase 2b Results for MET-097i

Summary

On September 29, 2025, Metsera, Inc. announced positive topline data from two Phase 2b trials of MET-097i, a GLP-1 receptor agonist. In VESPER-1, the drug demonstrated mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses, with potentially class-leading tolerability. The company plans to initiate a global Phase 3 program in late 2025 based on these results.